Rallybio Corp (RLYB): Price and Financial Metrics


Rallybio Corp (RLYB): $7.03

0.09 (+1.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RLYB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RLYB Stock Price Chart Interactive Chart >

Price chart for RLYB

RLYB Price/Volume Stats

Current price $7.03 52-week high $15.89
Prev. close $6.94 52-week low $4.54
Day low $7.00 Volume 1,151
Day high $7.03 Avg. volume 54,212
50-day MA $6.10 Dividend yield N/A
200-day MA $9.09 Market Cap 225.21M

Rallybio Corp (RLYB) Company Bio


Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.


RLYB Latest News Stream


Event/Time News Detail
Loading, please wait...

RLYB Latest Social Stream


Loading social stream, please wait...

View Full RLYB Social Stream

Latest RLYB News From Around the Web

Below are the latest news stories about RALLYBIO CORP that investors may wish to consider to help them evaluate RLYB as an investment opportunity.

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023

NEW HAVEN, Conn., January 05, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected 2023 clinical milestones. The Company will present these updates at the 41st Annual J.P. Morgan Health Care Conference in San Francisco, California on Tuesday, January 10, 2023, at

Yahoo | January 5, 2023

Rallybio Corporation (NASDAQ:RLYB) Shares Are Up 22.39% From The Lows, But Can They Stay Up?

In last trading session, Rallybio Corporation (NASDAQ:RLYB) saw 0.42 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $5.85 trading at -$1.17 or -16.67% at ring of the bell on the day assigns it a market valuation of $210.37M. That closing price of RLYB’s stock is at … Rallybio Corporation (NASDAQ:RLYB) Shares Are Up 22.39% From The Lows, But Can They Stay Up? Read More »

Marketing Sentinel | December 17, 2022

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

NEW HAVEN, Conn., December 15, 2022--Rallybio Corporation (Nasdaq: RLYB) today announced publication of preclinical study results for two human HPA-1a-specific antibodies in development for the prevention of FNAIT. The results demonstrate that low doses of the two HPA-1a-specific antibodies, the polyclonal candidate RLYB211 and the monoclonal candidate RLYB212, are equally effective at rapidly clearing HPA-1a-positive platelets from circulation and preventing alloimmunization to HPA-1a. As expec

Yahoo | December 15, 2022

The Rallybio Corporation (RLYB) had a good session last reading, didn’t it?

Rallybio Corporation (NASDAQ:RLYB) marked $5.90 per share on Tuesday, up from a previous closing price of $4.67. While Rallybio Corporation has overperformed by 26.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RLYB fell by -39.86%, with highs and lows ranging from $15.89 to $4.54, whereas […]

US Post News | December 14, 2022

Rallybio Corporation (NASDAQ:RLYB) insiders are still down US$129k after purchasing last year, recent gain helped regain some losses

Some of the losses seen by insiders who purchased US$332k worth of Rallybio Corporation ( NASDAQ:RLYB ) shares over the...

Yahoo | December 14, 2022

Read More 'RLYB' Stories Here

RLYB Price Returns

1-mo N/A
3-mo -16.31%
6-mo -37.51%
1-year -49.42%
3-year N/A
5-year N/A
YTD 7.00%
2022 -31.13%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5767 seconds.